文献速递湿疹皮炎与荨麻疹

美加儿童重度特应性皮炎系统用药处方实践:PeDRA TREAT调查

Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey.
PubMed 文献 · J Am Acad Dermatol · 2016-11-14

该调查由儿科皮肤病研究联盟(PeDRA)TREAT工作组开展,面向美国与加拿大儿科皮肤科医生,评估儿童重度特应性皮炎(AD)系统免疫调节剂处方实践。290名学会成员中133名(45.9%)完成调查,其中115名(86.5%)使用系统治疗;一线选择以环孢素(45.2%)、甲氨蝶呤(29.6%)和吗替麦考酚酯(13.0%)为主,二线最常用甲氨蝶呤(31.3%)和吗替麦考酚酯(30.4%)。主要阻碍因素为副作用特征(82.6%)和长期毒性风险担忧(81.7%),结论认为美加医生处方实践差异较大。

要点

  • 美加儿科皮肤科医生对儿童重度AD系统用药选择差异大,一线以环孢素为主。
  • 二线常用甲氨蝶呤和吗替麦考酚酯,硫唑嘌呤多作为三线。
  • 副作用与长期毒性担忧是限制系统用药的主要因素。

核心结论

  • 美国与加拿大医生在儿童重度AD系统用药处方实践上存在较大差异。

研究设计与样本

  • PeDRA TREAT工作组开发在线多选问卷,调查美加儿科皮肤科医生对儿童重度AD的系统用药实践。
  • 290名儿科皮肤病学会成员中133名(45.9%)完成调查,其中115名(86.5%)使用系统治疗。

主要发现

  • 一线药物选择:环孢素45.2%、甲氨蝶呤29.6%、吗替麦考酚酯13.0%。
  • 最常用二线药物:甲氨蝶呤31.3%、吗替麦考酚酯30.4%;硫唑嘌呤为最常提及的三线药物。
  • discouraging系统用药的主要因素:副作用特征82.6%、长期毒性风险担忧81.7%。

临床怎么用

  • 调查结果提示儿童重度AD系统用药缺乏统一处方标准,临床选择需结合药物副作用与长期毒性风险。

局限性

  • 未充分调查系统药物使用顺序或联合系统治疗。
  • 回忆偏倚可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a paucity of literature to direct physicians in the prescribing of immunomodulators for patients with severe atopic dermatitis (AD). OBJECTIVE: To survey systemic agent prescribing practices for severe childhood AD among clinicians in the United States and Canada. METHODS: The TREatment of severe Atopic dermatitis in children Taskforce (TREAT), US&CANADA, a project of the Pediatric Dermatology Research Alliance (PeDRA), developed an online multiple-response survey to assess clinical practice, gather demographic information and details of systemic agent selection, and identify barriers to their use in patients with recalcitrant pediatric AD. RESULTS: In total, 133 of 290 members (45.9%) of the Society for Pediatric Dermatology completed the survey, and 115 of 133 (86.5%) used systemic treatment for severe pediatric AD. First-line drugs of choice were cyclosporine (45.2%), methotrexate (29.6%), and mycophenolate mofetil (13.0%). The most commonly used second-line agents were methotrexate (31.3%) and mycophenolate mofetil (30.4%); azathioprine was the most commonly cited third-line agent. The main factors that discouraged use of systemic agents were side-effect profiles (82.6%) and perceived risks of long-term toxicity (81.7%). LIMITATIONS: Investigation of the sequence of systemic medications or combination systemic therapy was limited. Recall bias may have affected the results. CONCLUSION: Great variation exists in prescribing practices among American and Canadian physicians using systemic agents for treatment of pediatric AD.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Totri CR, Eichenfield LF, Logan K, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. J Am Acad Dermatol. 2016. PMID: 27855965. doi:10.1016/j.jaad.2016.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。